Discovery of novel HIV entry inhibitors for the CXCR4 receptor by prospective virtual screening

Journal of Chemical Information and Modeling

Volumn 49, Issue 4, 2009, Pages 810-823

  Pérez Nueno, Violeta I ^a   Pettersson, Sofia ^a   Ritchie, David W ^b   Borrell, José I ^a   Teixidó, Jordi ^a  

^a INSTITUT QUÍMIC DE SARRIÀ   (Spain)

^b LORIA   (France)

Author keywords

[No Author keywords available]

Indexed keywords

DISEASES; LIGANDS; SYNTHESIS (CHEMICAL); VIRUSES;

ANTI-HIV COMPOUNDS; COMPUTATIONAL TOOLS; ENRICHMENT FACTORS; ENVELOPE GLYCOPROTEINS; HIV ENTRY INHIBITORS; MOLECULAR SCAFFOLDS; VIRTUAL LIBRARIES; VIRTUAL SCREENING;

DIGITAL LIBRARIES;

CHEMOKINE RECEPTOR CXCR4; HUMAN IMMUNODEFICIENCY VIRUS FUSION INHIBITOR; LIGAND;

ARTICLE; CHEMICAL STRUCTURE; CHEMISTRY; COMBINATORIAL CHEMISTRY; COMPUTER SIMULATION; CONFORMATION; DRUG ANTAGONISM; DRUG SCREENING; HUMAN; METHODOLOGY; QUANTITATIVE STRUCTURE ACTIVITY RELATION;

COMBINATORIAL CHEMISTRY TECHNIQUES; COMPUTER SIMULATION; DRUG EVALUATION, PRECLINICAL; HIV FUSION INHIBITORS; HUMANS; LIGANDS; MODELS, MOLECULAR; MOLECULAR CONFORMATION; QUANTITATIVE STRUCTURE-ACTIVITY RELATIONSHIP; RECEPTORS, CXCR4;

EID: 66149114339     PISSN: 15499596     EISSN: 1549960X     Source Type: Journal    
DOI: 10.1021/ci800468q     Document Type: Article

References (62)

1. UNAIDS. AIDS epidemic update: December 2007. http://www.un-aids.org/en/ KnowledgeCentre/HIVData/EpiUpdate/EpiUpdArchive/2007/default.asp (accessed Nov 11, 2008).
2. De Clercq, E. Emerging anti-HIV drugs. Expert Opin. Emersins Drugs 2005, 10, 241-274.
3. De Clercq, E. Anti-HIV chemotherapy: current state of the art. Med. Chem. Res. 2004, 13, 439-478.
4. Kadow, J.; Wang, H. G.; Lin, P. F. Small-molecule HIV-1 gpl20 inhibitors to prevent HIV-1 entry: an emerging opportunity for drug development. Curr. Opin. Invest. Drugs (Thomson Sci.) 2006, 7, 721-726.
5. Berger, E. A.; Murphy, P. M.; Färber, J. M. Chemokine receptors as HIV-1 coreceptors: Roles in viral entry, tropism, and disease. Annu. Rev. Immunol. 1999, 17, 657-700.
6. Jiang, S.; Lin, K.; Strick, N.; Neurath, A. R. Inhibition of HIV-1 infection by a fusion domain binding peptide from the HIV-1 envelope glycoprotein GP41. Biochem. Biophvs. Res. Commun. 1993, 195, 533-538.
7. De Clercq, E. New antiviral agents in preclinical or clinical development. Adv. Antiviral Drug Des. 2004, 4, 1-62.
8. De Clercq, E. New Anti-HIV Agents and Targets. Med. Res. Rev. 2002, 22, 531-565.
9. Bean, P. New Drugs Targets for HIV. Clin. Infect. Dis. 2005, 41, 96-100.
10. Markovic, I.; Clouse, K. A. Recent advances in understanding the molecular mechanisms of HIV-1 entry and fusion: revisiting current targets and considering new options for therapeutic intervention. Curr. HIV Res. 2004, 2, 223-34.
11. Kazmierski, W. M.; Peckman, J. P.; Duan, M.; Kenakin, T. P.; Jenkinson, S.; Gudmundsson, K. S.; Piscitelli, S. C.; Feldman, P. L. Recent Progress in the Discovery of New CCR5 and CXCR4 Chemokine Receptor Antagonists as Inhibitors of HIV-1 Entry. Part 2. Curr. Med. Chem. - Anti Infect. Asents 2005, 4, 133-152.
12. Pettersson, S.; Pérez-Nueno, V. I.; Ros-Blanco, L.; Puig de la Bellacasa, R.; Rabal, O.; Batllori, X.; Clotet, B.; Clotet-Codina, L.; Armand-Ugón, M.; Esté, J.; Borrell, J. L.; Teixidó, J. Discovery of novel non-cyclam polynitrogenated CXCR4 coreceptor inhibitors. ChemMedChem 2008, 3, 1549-1557.
13. Maybridge Bringing life to drug discovery; Maybridge Databases Autumn 2005; Fisher Scientific International: England, 2005.
14. Pascual, R.; Borrell, J. I.; Teixido, J. Analysis of selection methodologies for combinatorial library design. Mol. Diversity 2003, 6, 121-133.
15. MOE (Molecular Operating Environment), 2006.08 Release; Chemical Computing Group, Inc.: Montreal, Canada, 2004.
16. Discovery Studio, version 2.0; Accelrys Software Inc.: San Diego, 2007.
17. Lin, J.; Clark, T. An analytical, variable resolution, complete description of static molecules and their intermolecular binding properties. J. Chem. Inf. Model. 2005, 45, 1010-1016.
18. Grant, A. J.; Pickup, B. T. A fast method of molecular shape comparison: a simple application of a Gaussian description of molecular shape. J. Comput. Chem. 1996, 17, 1653-1659.
19. Ritchie, D. W.; Kemp, G. J. L. Fast computation, rotation, and comparison of low resolution spherical harmonic molecular surfaces. J. Comput. Chem. 1999, 20, 383-395.
20. Pérez-Nueno, V. I.; Ritchie, D. W.; Rabal, O.; Pascual, R.; Borrell, J. L.; Teixidó, J. Comparison of Ligand-Based and Receptor-Based Virtual Screening of HIV Entry Inhibitors for the CXCR4 and CCR5 Receptors Using 3D Ligand Shape-matching and Ligand-Receptor Docking. J. Chem. Inf. Model. 2008, 48, 509-533.
21. Palczewski, K.; Kumasaka, T.; Hori, T.; Behnke, C. A.; Motoshima, H.; Fox, B. A.; Le Trong, I.; Teller, D. C.; Okada, T.; Stenkamp, R. E.; Yamamoto, M.; Miyano, M. Crystal structure of rhodopsin: A G-protein-coupled receptor. Science 2000, 289, 739-745.
22. Morris, G. M.; Goodsell, D. S.; Halliday, R. S.; Hart, W.; Belew, R. K.; Olson, A. J. Automated Docking Using a Lamarckian Genetic Algorithm and Empirical Binding Free Energy Function. J. Comput. Chem. 1998, 19, 1639-1662.
23. Verdonk, M. L.; Cole, J. C.; Hartshorn, M. J.; Murray, C. W.; Taylor, R. D. Improved Protein-Ligand Docking Using GOLD. Proteins: Struct. Funct. Genet. 2003, 52, 609-623.
24. McGann, M. R.; Almond, H. R.; Nicholls, A.; Grant, J. A.; Brown, F. K. Gaussian docking functions. Biopolymers 2003, 68, 76-90.
25. Ritchie, D. W.; Kemp, G. J. L. Protein docking using spherical polar Fourier correlations. Proteins;Struct Funct Genet 2000, 39, 178-194.
26. Hatse, S.; Princen, K.; De Clercq, E.; Rosenkilde, M. M.; Schwartzb, T. W.; Hernandez-Abad, P. E.; Skerlj, R. T.; Bridger, G. J.; Schols, D. AMD3465, a monomacrocyclic CXCR4 antagonist and potent HIV entry inhibitor. Biochem. Pharmacol. 2005, 70, 752-761.
27. Princen, K.; Hatse, S.; Vermeire, K.; Aquaro, S.; De Clercq, E.; Gerlach, L.-O.; Rosenkilde, M.; Schwartz, T. W.; Skerlj, R.; Bridger, G.; Schols, D. Inhibition of Human Immunodeficiency Virus Replication by a Dual CCR5/CXCR4 Antagonist. J. Virol. 2004, 78, 12996-13006.
28. Rosenkilde, M. M.; Gerlach, L.-O.; Hatse, S.; Skerlj, R. L.; Schols, D.; Bridger, G.; Schwartz, T. W. Molecular mechanism of action of monocyclam versus bicyclam non-peptide antagonist in the CXCR4 chemokine receptor. J. Biol. Chem. 2007, 282, 27354-27365.
29. Teixidó, J.; Borrell, J. I.; Nonell, S.; Pettersson, S.; Ros, L.; Puig de la Bellacasa, R.; Rabal, M. O.; Pérez-Nueno, V. L.; Esté, J.; Clotet-Codina, L.; Armand-Ugón, M. Nuevos sistemas polinitrogenados como agentes anti-VIH. ES Patent ES200602764, 2006 (filing date: October 26, 2006).
30. Bridger, G.; Skerlj, R.; Kaller, A.; Harwing, C.; Bogucki, D.; Wilson, T. R.; Crawford, J.; McEachern, E. J.; Atsma, B.; Nan, S.; Zhou, Y. World Patent WO 0022600, 2002.
31. Bridger, G.; Skerlj, R.; Kaller, A.; Harwing, C.; Bogucki, D.; Wilson, T. R.; Crawford, J.; McEachern, E. J.; Atsma, B.; Nan, S.; Zhou, Y. World Patent WO 0022599, 2002.
32. Bridger, G.; Skerlj, R.; Kaller, A.; Harwing, C.; Bogucki, D.; Wilson, T. R.; Crawford, J.; McEachern, E. J.; Atsma, B.; Nan, S.; Zhou, Y. World Patent WO 00234745, 2002.
33. Bridger, G.; Skerlj, R.; Kaller, A.; Harwing, C.; Bogucki, D.; Wilson, T. R.; Crawford, J.; McEachern, E. J.; Atsma, B.; Nan, S.; Zhou, Y. World Patent WO 055876, 2003.
34. Bridger, G.; Skerlj, R.; Kaller, A.; Harwing, C.; Bogucki, D.; Wilson, T. R.; Crawford, J.; McEachern, E. J.; Atsma, B.; Nan, S.; Zhou, Y.; Smith, C. D.; Di Fluir, R. M. U.S. Patent 0019058, 2004.
35. Ichiyama, K.; Yokohama-Kumakura, S.; Tanaka, Y.; Tanaka, R.; Hirose, K.; Bannai, K.; Edamatsu, T.; Yanaka, M.; Niitani, Y.; Miyako-Kurosaki, N.; Takaku, H.; Koyanagi, Y.; Yamamoto, N. Proc. Natl. Acad. Sci. U.S.A. 2003, 100, 4185-4190.
36. Murakami, T.; Yoshida, A.; Tanaka, R.; Mitsuhashi, S.; Hirose, K.; Yanaka, M.; Yamamato, N.; Tanaka, Y. KRH-2731: An Orally Bioavailable CXCR4 Antagonist Is a Potent Inhibitor of HIV-1 Infection. In 2004 Antivirals Pipeline Report; Camp, R., Ed.; Proceed-ings of the 11th Conference on Retroviruses and Opportunistic Infections, San Francisco, CA, Feb 8-11, 2004; Treatment Action Group: San Francisco, CA, 2004; Abstract No. 541.
37. Yamazaki, T.; Saitou, A.; Ono, M.; Yokohama, S.; Bannai, K.; Hiroswe, K.; Yanaka, M. World Patent WO 029218, 2003.
38. Yamazaki, T.; Kikumoto, S.; Ono, M.; Saitou, A.; Takahashi, H.; Kumakura, S.; Hirose, K. World Patent WO 024697, 2004.
39. Bridger, G. J.; Skerlj, R. T.; Padmanabhan, S.; Martellucci, S. A.; Henson, G. H.; Struyf, S.; Witvrouw, M.; Schols, D.; De Clercq, E. Synthesis and Structure-Activity Relationships of Phenylenebis(m-ethylene)-Linked Bis-azamacrocycles That Inhibit HIV-1 and HIV-2 Replication by Antagonism of the Chemokine Receptor CXCR4. J. Med. Chem. 1999, 42, 3971-3981.
40. De Clercq, E. Inhibition of HIV Infection by Bicyclams, Highly Potent and Specific CXCR4 Antagonists. Mol. Pharmacol. 2000, 57, 833-839.
41. Esté, J. A.; Cabrera, C.; De Clercq, E.; Struyf, S.; Damme, J. V.; Bridger, G.; Skerlj, R. T.; Abrams, M. J.; Henson, G.; Gutierrez, A.; Clotet, B.; Schols, D. Activity of Different Bicyclam Derivatives against Human Immunodeficiency Virus Depends on Their Interaction with the CXCR4 Chemokine Receptor. Mol. Pharmacol. 1999, 55, 67-73.
42. Egberink, H. F.; De Clercq, E.; Van Vliet, A. L. W.; Balzarini, J.; Bridger, G. J.; Henson, G.; Horzinek, M. C.; Schols, D. Bicyclams, Selective Antagonists of the Human Chemokine Receptor CXCR4, Potently Inhibit Feline Immunodeficiency Virus Replication. J. Virol. 1999, 73, 6346-6352.
43. Tamamura, H.; Araki, T.; Ueda, S.; Wang, Z.; Oishi, S.; Esaka, A.; Trent, J. O.; Nakashima, H.; Yamamoto, N.; Peiper, S. C.; Otaka, A.; Fujii, N. Identification of novel low molecular weight CXCR4 antagonists by structural tuning of cyclic tetrapeptide scaffolds. J. Med. Chem. 2005, 48, 3280-3289.
44. Gerlach, L.-O.; Skerlj, R. T.; Bridger, G. J.; Schwartz, T. W. Molecular Interaction of Cyclam and Bicyclam Non-peptide Antagonists with the CXCR4 Chemokine Receptor. J. Biol. Chem. 2001, 276, 14154-14160.
45. Tamamura, H.; Ojida, A.; Ogawa, T.; Tsutsumi, H.; Masuno, H.; Nakashima, H.; Yamamoto, N.; Hamachi, I.; Fujii, N. Identification of a new class of low molecular weight antagonists against the chemokine receptor CXCR4 having the dipicolylamine-zinc(II) complex structure. J. Med. Chem. 2006, 49, 3412-3415.
46. Labute, P. Flexible Alignment of Small Molecules. Chemical Computing Group, Inc.: Montreal, Canada, 2004. (Available on the Internet at http:/www.chemcomp.com/journal/malign.htm (accessed June 2, 2008)).
47. Agrawal, V. K.; Singh, J.; Gupta, M.; Jaliwala, Y. A.; Khadikar, P. V.; Supuran, C. T. QSAR studies on benzopyran potassium channel activators. Eur. J. Med. Chem. 2006, 41, 360-366.
48. Golbraikh, A.; Shen, M.; Xiao, Z.; Xiao, Y.-D.; Lee, K.-H.; Tropsha, A. Rational selection of training and test sets for the development of validated QSAR models. J. Comput. -Aided Mol. Des. 2003, 17, 241-253.
49. Golbraikh, A.; Tropsha, A. Beware of q2! J. Mol. Graphics Modell. 2002, 20, 269-276.
50. OMEGA, version 2.1.0; OpenEye Scientific Software Inc.: Santa Fe, NM., 2006.
51. Pérez-Nueno, V. I.; Ritchie, D. W.; Borrell, J. L.; Teixidó, J. Clustering and classifying diverse HIV entry inhibitors using a novel consensus shape based virtual screening approach: Further evidence for multiple binding sites within the CCR5 extracellular pocket. J. Chem. Inf. Model. 2008, 48, 2146-2165.
52. Hatse, S.; Princes, K.; Vermeire, K.; Gerlach, L.-O.; Rosenkilde, M. M.; Schwartz, T. W.; Bridger, G.; De Clercq, E.; Schols, D. Mutations at the CXCR4 interaction sites for AMD3100 influence anti-CXCR4 antibody binding and HIV-1 entry. FEBS Lett. 2003, 546, 300-306.
53. Brelot, A.; Heveker, N.; Montes, M.; Alizon, M. Identification of Residues of CXCR4 Critical for Human Immunodeficiency Virus Coreceptor and Chemokine Receptor Activities. J. Biol. Chem. 2000, 275, 23736-23744.
54. Hatse, S.; Princen, K.; Gerlach, L.-O.; Bridger, G.; Henson, G.; Clercq, E.; Schwartz, T. W.; Schols, D. Mutation of Aspl71 and Asp262 of the chemokine receptor CXCR4 impairs its coreceptor function for human immunodeficiency virus-1 entry and abrogates the antagonistic activity of AMD3100. Mol. Pharmacol. 2001, 60, 164-173.
55. Wang, R.; Wang, S. How does consensus scoring work for virtual library screening? An idealized computer experiment. J. Chem. Inf. Comput. Sci. 2001, 41, 1422-1426.
56. Güner, O. F.; Henry, D. R. Metric for analyzing hit lists and pharmacophores. Chapter 11. In Pharmacophore, perception, development and use in drug design; Güner, O. F., Ed.; International University Line: La Jolla, CA, 2000; pp 195-212.
57. Gürner, O. F.; Hoffman, R.; Li, H. Techniques and strategies in 3D data mining. In Report by Wendy A. Warr; 217th ASC National Metting and Exposition, Anaheim, California, March 12-25, 1999; Wendy Warr & Associates: London, 1999; pp 50-53.
58. Hunter, T. M.; McNae, I. W.; Simpson, D. P.; Smith, A. M.; Moggach, S.; White, F.; Walkinshaw, M. D.; Parsons, S.; Sadler, P. J. Configurations of nickel-cyclam antiviral complexes and protein recognition. Chem.-Eur. J. 2007, 13, 40-50.
59. Liang, X.; Parkinson, J. A.; Wishäupl, M.; Gould, R. O.; Paisey, S. J.; Park, H.; Hunter, T. M.; Blindauer, C. A.; Parsons, S.; Sadler, P. J. Structure and dynamics of metailomacrocycles: recognition of zinc xylyxl-bicyclam by an HIV coreceptor. J. Am. Chem. Soc. 2002, 124, 9105-9112.
60. Hunter, T. M.; McNae, I. W.; Liang, X.; Bella, J.; Parsons, S.; Walkinshaw, M. D.; Sadler, P. J. Protein recognition of macrocycles: Binding of anti-HIV metallocyclams to lysozyme. Proc. Natl. Acad. Sci. U.S.A. 2005, 102, 2288-2292.
61. Rosenkilde, M. M.; Gerlach, L.-O.; Jakobsern, J. S.; Skerlj, R. T.; Bridger, G. J.; Schwartz, T. W. Molecular mechanism of AMD3100 antagonism in the CXCR4 receptor. J. Biol. Chem. 2004, 279, 3033-3041.
62. Valks, G. C.; McRobbie, G.; Lewis, E. A.; Hubin, T. J.; Hunter, T. M.; Sadler, P. J.; Pannecouque, C.; De Clercq, E.; Archibald, S. J. Configurationally restricted bismacrocyclic CXCR4 receptor antagonists. J. Med. Chem. 2006, 49, 6162-6165.